Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2007, Article ID 27683, 10 pages
http://dx.doi.org/10.1155/2007/27683
Research Article

Characterization of the De Novo Biosynthetic Enzyme of Platelet Activating Factor, DDT-Insensitive Cholinephosphotransferase, of Human Mesangial Cells

1Faculty of Chemistry, School of Sciences, National and Kapodistrian University of Athens, Panepistimioupolis, Athens 15771, Greece
2Department of Science of Dietetics and Nutrition, Harokopio University, 70 El. Venizelou Street, Athens 176 71, Greece
3Centre for Nephrology, G. Papadakis General Hospital of Nikea-Pireaus, 3 Mandouvalou Street, Athens 18454, Greece

Received 24 January 2007; Accepted 8 March 2007

Copyright © 2007 Alexandros Basilios Tsoupras et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. A. Demopoulos, R. N. Pinckard, and D. J. Hanahan, “Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators),” The Journal of Biological Chemistry, vol. 254, no. 19, pp. 9355–9358, 1979. View at Google Scholar
  2. J. Benveniste, M. Tencé, P. Varenne, J. Bidault, C. Boullet, and J. Polonsky, “Semi-synthesis and proposed structure of platelet-activating factor (P.A.F.): PAF-acether an alkyl ether analog of lysophosphatidylcholine,” Comptes Rendus des Séances de l'Académie des Sciences. Série D, Sciences Naturelles, vol. 289, no. 14, pp. 1037–1040, 1979. View at Google Scholar
  3. M. L. Blank, F. Snyder, L. W. Byers, B. Brooks, and E. E. Muirhead, “Antihypertensive activity of an alkyl ether analog of phosphatidylcholine,” Biochemical and Biophysical Research Communications, vol. 90, no. 4, pp. 1194–1200, 1979. View at Google Scholar
  4. S. M. Prescott, G. A. Zimmerman, D. M. Stafforini, and T. M. McIntyre, “Platelet-activating factor and related lipid mediators,” Annual Review of Biochemistry, vol. 69, pp. 419–445, 2000. View at Publisher · View at Google Scholar
  5. F. Snyder, V. Fitzgerald, and M. L. Blank, “Biosynthesis of platelet-activating factor and enzyme inhibitors,” Advances in Experimental Medicine and Biology, vol. 416, pp. 5–10, 1996. View at Google Scholar
  6. D. M. Stafforini, T. M. McIntyre, M. E. Carter, and S. M. Prescott, “Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor,” The Journal of Biological Chemistry, vol. 262, no. 9, pp. 4215–4222, 1987. View at Google Scholar
  7. E. Francescangeli, A. Boila, and G. Goracci, “Properties and regulation of microsomal PAF-synthesizing enzymes in rat brain cortex,” Neurochemical Research, vol. 25, no. 5, pp. 705–713, 2000. View at Publisher · View at Google Scholar
  8. F. Snyder, “CDP-choline:alkylacetylglycerol cholinephosphotransferase catalyzes the final step in the de novo synthesis of platelet-activating factor,” Biochimica et Biophysica Acta, vol. 1348, no. 1-2, pp. 111–116, 1997. View at Publisher · View at Google Scholar
  9. K. Muguruma and J. M. Johnston, “Metabolism of platelet-activating factor in rat epididymal spermatozoa,” Biology of Reproduction, vol. 56, no. 2, pp. 529–536, 1997. View at Publisher · View at Google Scholar
  10. B. O. Ibe, A. M. Portugal, and J. Usha Raj, “Metabolism of platelet activating factor by intrapulmonary vascular smooth muscle cells. Effect of oxygen on phospholipase A2 protein expression and activities of acetyl-CoA acetyltransferase and cholinephosphotransferase,” Molecular Genetics and Metabolism, vol. 77, no. 3, pp. 237–248, 2002. View at Publisher · View at Google Scholar
  11. N. Satoh, A. Harada, K. Yokoyama, K. Karasawa, K. Inoue, and M. Setaka, “Regulation of activities of cytidine 5-diphospho-choline:1-O-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase, an enzyme responsible for de novo synthesis of platelet-activating factor, by membrane phospholipids,” Journal of Health Science, vol. 49, no. 1, pp. 13–21, 2003. View at Publisher · View at Google Scholar
  12. R. Giménez and J. Aguilar, “Cytidine (5) diphosphocholine-induced decrease in cerebral platelet activating factor is due to inactivation of its synthesizing enzyme cholinephosphotransferase in aged rats,” Neuroscience Letters, vol. 299, no. 3, pp. 209–212, 2001. View at Publisher · View at Google Scholar
  13. M. Imagawa, H. Mimata, S.-I. Takahashi, M. Nakagawa, Y. Nomura, and J. Ogata, “Modulation of platelet-activating factor synthesis by recombinant interferon-α in human renal cell carcinoma,” Urologia Internationalis, vol. 57, no. 1, pp. 11–16, 1996. View at Google Scholar
  14. W. Renooij and F. Snyder, “Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor and a hypotensive lipid) by cholinephosphotransferase in various rat tissues,” Biochimica et Biophysica Acta, vol. 663, no. 2, pp. 545–556, 1981. View at Google Scholar
  15. X. E. Wells and C. O'Neill, “Detection and preliminary characterization of two enzymes involved in biosynthesis of platelet-activating factor in mouse oocytes, zygotes and preimplantation embryos: dithiothreitol-insensitive cytidinediphosphocholine: 1-O-alkyl-2-acetyl-sn-glycerol cholinephosphotransferase and acetyl-coenzyme A:1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine acetyltransferase,” Journal of Reproduction and Fertility, vol. 101, no. 2, pp. 385–391, 1994. View at Google Scholar
  16. D. Schlondorff and R. Neuwirth, “Platelet-activating factor and the kidney,” The American Journal of Physiology, vol. 251, no. 1, part 2, pp. F1–F11, 1986. View at Google Scholar
  17. G. Camussi, “Potential role of platelet-activating factor in renal pathophysiology,” Kidney International, vol. 29, no. 2, pp. 469–477, 1986. View at Google Scholar
  18. J. M. López-Novoa, “Potential role of platelet activating factor in acute renal failure,” Kidney International, vol. 55, no. 5, pp. 1672–1682, 1999. View at Publisher · View at Google Scholar
  19. A. Ortiz, M. Gomez-Chiarri, J. L. Lerma, E. Gonzalez, and J. Egido, “The role of platelet-activating factor (PAF) in experimental glomerular injury,” Lipids, vol. 26, no. 12, pp. 1310–1315, 1991. View at Publisher · View at Google Scholar
  20. S. Antonopoulou, C. A. Demopoulos, C. Iatrou, G. Moustakas, and P. Zirogiannis, “Platelet-activating factor acetylhydrolase (PAF-AH) in human kidney,” International Journal of Biochemistry, vol. 26, no. 9, pp. 1157–1162, 1994. View at Publisher · View at Google Scholar
  21. T. Nomikos, C. Iatrou, and C. A. Demopoulos, “Acetyl-CoA:1-O-alkyl-sn-glycero-3-phosphocholine acetyltransferase (lyso-PAF AT) activity in cortical and medullary human renal tissue,” European Journal of Biochemistry, vol. 270, no. 14, pp. 2992–3000, 2003. View at Publisher · View at Google Scholar
  22. T. Nomikos, C. Iatrou, and C. A. Demopoulos, “Application of a TCA-precipitation method for the determination of 1-alkyl-sn-glycero-3-phosphate:acetyl-CoA acetyltransferase in human renal tissue,” Prostaglandins and Other Lipid Mediators, vol. 73, no. 1-2, pp. 123–140, 2004. View at Publisher · View at Google Scholar
  23. E. Fragopoulou, C. Iatrou, and C. A. Demopoulos, “Characterization of acetyl-CoA: lyso-PAF acetyltransferase of human mesangial cells,” Mediators of Inflammation, vol. 2005, no. 5, pp. 263–272, 2005. View at Publisher · View at Google Scholar
  24. R. Neuwirth, N. Ardaillou, and D. Schlondorff, “Extra- and intracellular metabolism of platelet-activating factor by cultured mesangial cells,” The American Journal of Physiology, vol. 256, no. 4, part 2, pp. F735–F741, 1989. View at Google Scholar
  25. E. A. Lianos and A. Zanglis, “Biosynthesis and metabolism of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine in rat glomerular mesangial cells,” The Journal of Biological Chemistry, vol. 262, no. 19, pp. 8990–8993, 1987. View at Google Scholar
  26. H. C. Karantonis, N. Tsantila, S. Antonopoulou et al., “In vivo antiatherogenic properties of olive oil and its constituent lipid classes in hyperlipidemic rabbits,” Chemistry and Physics of Lipids, vol. 130, no. 1, p. 59, 2004. View at Google Scholar
  27. C. Nasopoulou, T. Nomikos, J. Rementzis, C. A. Demopoulos, and I. Zabetakis, “Biologically active lipid fractions in fish and cephalopods of the Mediterranean diet,” Chemistry and Physics of Lipids, vol. 130, no. 1, p. 63, 2004. View at Google Scholar
  28. J.-D. Sraer, F. Delarue, J. Hagege et al., “Stable cell lines of T-SV40 immortalized human glomerular mesangial cells,” Kidney International, vol. 49, no. 1, pp. 267–270, 1996. View at Google Scholar
  29. E. G. Bligh and W. J. Dyer, “A rapid method of total lipid extraction and purification,” Canadian Journal of Biochemistry and Physiology, vol. 37, no. 8, pp. 911–917, 1959. View at Google Scholar
  30. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, “Protein measurement with the Folin phenol reagent,” The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265–275, 1951. View at Google Scholar
  31. I. Izquierdo, M. Merlos, and J. García-Rafanell, “Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist—a review of pharmacological profile and clinical management of allergic rhinitis,” Drugs of Today, vol. 39, no. 6, pp. 451–468, 2003. View at Publisher · View at Google Scholar
  32. C. Cortese, S. Bernardini, and C. Motti, “Atherosclerosis in light of the evidence from large statin trials,” Annali Italiani di Medicina Interna, vol. 15, no. 1, pp. 103–107, 2000. View at Google Scholar
  33. N. W. C. J. van de Donk, A. C. Bloem, E. van der Spek, and H. M. Lokhorst, “New treatment strategies for multiple myeloma by targeting BCL-2 and the mevalonate pathway,” Current Pharmaceutical Design, vol. 12, no. 3, pp. 327–340, 2006. View at Publisher · View at Google Scholar
  34. D. Kardamakis, “Interferons in the treatment of malignancies,” In Vivo, vol. 5, no. 6, pp. 589–597, 1991. View at Google Scholar
  35. S. M. Cheer, C. J. Dunn, and R. Foster, “Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease,” Drugs, vol. 64, no. 13, pp. 1479–1502, 2004. View at Publisher · View at Google Scholar
  36. K. Norrby, “Low-molecular-weight heparins and angiogenesis,” Acta Pathologica, Microbiologica et Immunologica Scandinavica, vol. 114, no. 2, pp. 79–102, 2006. View at Publisher · View at Google Scholar
  37. H. Kulbertus, “Aspirin: recent advances in cardiovascular prevention,” Revue Medicale de Liege, vol. 59, no. 12, pp. 695–703, 2004. View at Google Scholar
  38. C. J. Buskens, A. Ristimäki, G. J. A. Offerhaus, D. J. Richel, and J. J. B. van Lanschot, “Role of cyclooxygenase-2 in the development and treatment of oesophageal adenocarcinoma,” Scandinavian Journal of Gastroenterology, vol. 38, no. 239, pp. 87–93, 2003. View at Publisher · View at Google Scholar
  39. C. Balestrieri, F. Felice, S. Piacente et al., “Relative effects of phenolic constituents from Yucca schidigera Roezl. bark on Kaposi's sarcoma cell proliferation, migration, and PAF synthesis,” Biochemical Pharmacology, vol. 71, no. 10, pp. 1479–1487, 2006. View at Publisher · View at Google Scholar
  40. H. C. Karantonis, S. Antonopoulou, D. N. Perrea et al., “In vivo antiatherogenic properties of olive oil and its constituent lipid classes in hyperlipidemic rabbits,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 16, no. 3, pp. 174–185, 2006. View at Publisher · View at Google Scholar
  41. Y. Z. H.-Y. Hashim, C. I. R. Gill, H. McGlynn, and I. R. Rowland, “Components of olive oil and chemoprevention of colorectal cancer,” Nutrition Reviews, vol. 63, no. 11, pp. 374–386, 2005. View at Publisher · View at Google Scholar
  42. C. Dentan, A. D. Tselepis, M. J. Chapman, and E. Ninio, “Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase,” Biochimica et Biophysica Acta, vol. 1299, no. 3, pp. 353–357, 1996. View at Publisher · View at Google Scholar
  43. F. Bussolino, G. Pescarmona, G. Camussi, and F. Gremo, “Acetylcholine and dopamine promote the production of platelet activating factor in immature cells of chick embryonic retina,” Journal of Neurochemistry, vol. 51, no. 6, pp. 1755–1759, 1988. View at Publisher · View at Google Scholar
  44. R. Heller, F. Bussolino, D. Ghigo et al., “Stimulation of platelet-activating factor synthesis in human endothelial cells by activation of the de novo pathway. Phorbol 12-myristate 13-acetate activates 1-alkyl-2-lyso-sn-glycero-3-phosphate:acetyl-CoA acetyltransferase and dithiothreitol-insensitive 1-alkyl-2-acetyl-sn-glycerol:CDP-choline cholinephosphotransferase,” The Journal of Biological Chemistry, vol. 266, no. 32, pp. 21358–21361, 1991. View at Google Scholar
  45. C. A. Demopoulos, H. C. Karantonis, and S. Antonopoulou, “Platelet activating factor—a molecular link between atherosclerosis theories,” European Journal of Lipid Science and Technology, vol. 105, no. 11, pp. 705–716, 2003. View at Publisher · View at Google Scholar
  46. M. Koltai, D. Hosford, P. Guinot, A. Esanu, and P. Braquet, “PAF: a review of its effects, antagonists and possible future clinical implications—part II,” Drugs, vol. 42, no. 2, pp. 174–204, 1991. View at Google Scholar